AR022250A1 - PHARMACEUTICAL CONTAINER OF USE FOR THE TREATMENT AND PREVENTION OF INFECTIONS BY THE VIRUS OF HEPATITIS B, PROCEDURE FOR THE TREATMENT OF PATIENTS OR PATIENTS SUSCEPTIBLE IN SUFFERING INFECTIONS BY THE VIRUS OF HEPATITIS B. - Google Patents

PHARMACEUTICAL CONTAINER OF USE FOR THE TREATMENT AND PREVENTION OF INFECTIONS BY THE VIRUS OF HEPATITIS B, PROCEDURE FOR THE TREATMENT OF PATIENTS OR PATIENTS SUSCEPTIBLE IN SUFFERING INFECTIONS BY THE VIRUS OF HEPATITIS B.

Info

Publication number
AR022250A1
AR022250A1 ARP000100107A ARP000100107A AR022250A1 AR 022250 A1 AR022250 A1 AR 022250A1 AR P000100107 A ARP000100107 A AR P000100107A AR P000100107 A ARP000100107 A AR P000100107A AR 022250 A1 AR022250 A1 AR 022250A1
Authority
AR
Argentina
Prior art keywords
hepatitis
virus
treatment
infections
patients
Prior art date
Application number
ARP000100107A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of AR022250A1 publication Critical patent/AR022250A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Envase farmacéutico que contiene como ingredientes activos (1) un agente antiviral activo contra el virus de la hepatitis B y (2) una vacuna parala profilaxis y/o tratamiento de la infeccion de la hepatitis B, siendo los ingredientes activosapropiad os para uso simultáneo o secuencial. Los compuestospreferidos son un análogo nucleosídico como agente antiviral, junto con una vacuna para el virus de la hepatitis B, la cual comprende un antígeno de superficiedel virus de la hepatitis B.Pharmaceutical container containing as active ingredients (1) an active antiviral agent against hepatitis B virus and (2) a vaccine for the prophylaxis and / or treatment of hepatitis B infection, the active ingredients being suitable for simultaneous use or sequential. Preferred compounds are a nucleoside analogue as an antiviral agent, together with a hepatitis B virus vaccine, which comprises a hepatitis B virus surface antigen.

ARP000100107A 1999-01-12 2000-01-11 PHARMACEUTICAL CONTAINER OF USE FOR THE TREATMENT AND PREVENTION OF INFECTIONS BY THE VIRUS OF HEPATITIS B, PROCEDURE FOR THE TREATMENT OF PATIENTS OR PATIENTS SUSCEPTIBLE IN SUFFERING INFECTIONS BY THE VIRUS OF HEPATITIS B. AR022250A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9900630 1999-01-12

Publications (1)

Publication Number Publication Date
AR022250A1 true AR022250A1 (en) 2002-09-04

Family

ID=10845878

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100107A AR022250A1 (en) 1999-01-12 2000-01-11 PHARMACEUTICAL CONTAINER OF USE FOR THE TREATMENT AND PREVENTION OF INFECTIONS BY THE VIRUS OF HEPATITIS B, PROCEDURE FOR THE TREATMENT OF PATIENTS OR PATIENTS SUSCEPTIBLE IN SUFFERING INFECTIONS BY THE VIRUS OF HEPATITIS B.

Country Status (19)

Country Link
EP (1) EP1140163A2 (en)
JP (1) JP2002534438A (en)
KR (1) KR20010090011A (en)
CN (1) CN1391482A (en)
AR (1) AR022250A1 (en)
AU (1) AU760574B2 (en)
BR (1) BR9916893A (en)
CA (1) CA2359110A1 (en)
CO (1) CO5241355A1 (en)
CZ (1) CZ20012544A3 (en)
HK (1) HK1041434A1 (en)
HU (1) HUP0105070A2 (en)
IL (1) IL144186A0 (en)
NO (1) NO20013337L (en)
NZ (1) NZ512890A (en)
PL (1) PL349347A1 (en)
TR (1) TR200102024T2 (en)
WO (1) WO2000041463A2 (en)
ZA (1) ZA200105690B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1733735B1 (en) 1998-05-22 2017-03-22 Ottawa Hospital Research Institute Methods and products for inducing mucosal immunity
CA2337743C (en) 1998-07-31 2015-07-07 Yoshihiro Oka Tumor antigen based on products of the tumor suppressor gene wt1
ES2298353T3 (en) 2001-03-22 2008-05-16 International Institute Of Cancer Immunology, Inc. MODIFIED WT1 PEPTIDE.
EP1447092A4 (en) * 2001-09-28 2007-07-11 Haruo Sugiyama Methods of inducing antigen-specific t cells
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
ZA200503511B (en) 2002-10-29 2006-10-25 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
US7956043B2 (en) 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
CN100443117C (en) * 2003-05-13 2008-12-17 深圳康泰生物制品股份有限公司 Hepatitis B treating vaccine prepn and its prepn process and use
US8541167B2 (en) 2004-06-03 2013-09-24 Saint Louis University Methods and compositions for vaccination
WO2008104133A1 (en) * 2007-02-28 2008-09-04 Centro De Ingeniería Genética Y Biotecnología Combination therapy for the treatment of chronic hepatitis b
US20220088188A1 (en) * 2018-12-24 2022-03-24 Grand Theravac Life Science (Nanjing) Co., Ltd. Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof
CN117120088A (en) * 2021-04-07 2023-11-24 电化株式会社 Adjuvant activity enhancer and adjuvant composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0414374B1 (en) * 1989-07-25 1997-10-08 Smithkline Biologicals S.A. Novel antigens and methods for their preparation
BR9908599A (en) * 1998-03-09 2000-11-14 Smithkline Beecham Biolog Combined vaccine compositions

Also Published As

Publication number Publication date
BR9916893A (en) 2001-11-20
CO5241355A1 (en) 2003-01-31
CN1391482A (en) 2003-01-15
CZ20012544A3 (en) 2002-01-16
WO2000041463A3 (en) 2000-11-09
NZ512890A (en) 2003-09-26
NO20013337L (en) 2001-08-17
KR20010090011A (en) 2001-10-17
CA2359110A1 (en) 2000-07-20
AU2100900A (en) 2000-08-01
AU760574B2 (en) 2003-05-15
WO2000041463A2 (en) 2000-07-20
IL144186A0 (en) 2002-05-23
EP1140163A2 (en) 2001-10-10
ZA200105690B (en) 2002-09-25
PL349347A1 (en) 2002-07-15
JP2002534438A (en) 2002-10-15
HK1041434A1 (en) 2002-07-12
TR200102024T2 (en) 2001-12-21
NO20013337D0 (en) 2001-07-05
HUP0105070A2 (en) 2002-04-29

Similar Documents

Publication Publication Date Title
UY26724A1 (en) METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUSES
TR199903053T2 (en) Benzimidazole trevleri.
ES2167061T3 (en) DOSAGE FORMS TO IMPROVE ERECTILE DYSFUNCTION IN MALE SEX PATIENTS.
PE20060149A1 (en) PHARMACEUTICAL FORMULATION TO TREAT HIV INFECTION
AR022250A1 (en) PHARMACEUTICAL CONTAINER OF USE FOR THE TREATMENT AND PREVENTION OF INFECTIONS BY THE VIRUS OF HEPATITIS B, PROCEDURE FOR THE TREATMENT OF PATIENTS OR PATIENTS SUSCEPTIBLE IN SUFFERING INFECTIONS BY THE VIRUS OF HEPATITIS B.
AR002255A1 (en) A COMPOSITION THAT INCLUDES A FORMULATION OF MICROFLUIDIZED ANTIGEN AND USES OF SUCH FORMULATION.
EA200200812A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING LOW DOSE OF ENTEKAVIR, AND ITS APPLICATION
AR005281A1 (en) ORAL PHARACEUTICAL COMPOSITION, PROCEDURES FOR ITS MANUFACTURE AND USE OF THAT PHARMACEUTICAL COMPOSITION FOR THE PREPARATION OF MEDICINES. .
SV2004001556A (en) ACID PREPARATIONS OF INSULIN WITH IMPROVED STABILITY
ES2081531T3 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING RIFAXIMINE FOR THE TREATMENT OF VAGINAL INFECTIONS.
AR023806A1 (en) USE OF A PEPTIDE MIXTURE FOR THE MANUFACTURE OF A THERAPEUTIC AGENT FOR PROFILAXIS AND / OR CANCER TREATMENT, PHARMACEUTICAL COMPOSITIONS AND VACCINES CONTAINING SUCH MIXTURE AND THE PROCEDURES FOR PREPARATION OF THESE COMPOSITIONS
AR032151A1 (en) USE OF AN ANTI-ANGIOGENIC PHARMACO IN CONJUNCTION WITH A PHOTOSENSIBLE AGENT FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE IMPROVED PHOTODYNAMIC TREATMENT OF INDOVATED NEOVASCULATURE
AR026254A1 (en) THE USE OF A CONTROLLED RELEASE PREPARATION FOR THE PREPARATION OF A MEDICINAL PRODUCT TO INCREASE THE DOSE OR SYSTEM EXPOSURE OF A PHARMACO THAT INHIBITS PHOSPHODESTERASE 4
AR046402A1 (en) COMBINATION OF ACTIVE PRINCIPLE THAT INCLUDES A 2,5-DIHYDROBENCENOSULPHONIC COMPOUND AND A POTASSIUM CHANNEL MODULATOR
NO970847D0 (en) 2- [Amino-6- (cyclopropylamino) -9H-purin-9-yl] -2-cyclopenten-1-methanol succinate as anti-viral agent
ECSP003685A (en) ORAL FORMULATIONS OF CONTROLLED RELEASE
ECSP003859A (en) COMPOSITION FOR THE TREATMENT OF DAMAGED FABRICS
ES2148234T3 (en) PHARMACEUTICAL COMPOSITION BASED ON FLAVOPEREIRIN AND ITS USE IN THE TREATMENT OF HIV VIRUSES.
AR005730A1 (en) FORM OF FANCICLOVIR, PROCEDURE FOR PREPARING IT, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT AND METHOD FOR THE TREATMENT OR PROPHYLAXIS OF VIRAL INFECTIONS AND THE USE OF SUCH FORM -FANCICLOVIR MONOIDRATE.
KR960700741A (en) METHOD OF TREATING HEPATITIS C IN NON-PESPONDERS TO INTERFERON TREATMENT
CO5160259A1 (en) INTERFERON ALFA PEGILADO IN THE THERAPY AGAINST HIV
AR027037A1 (en) COMPOSITE AND METHOD FOR PAIN TREATMENT
ES2130069B1 (en) PHARMACEUTICAL PREPARATION WITH DELAYED RELEASE OF THE ACTIVE PRODUCT.
CO4790095A1 (en) THENOXACINONE DERIVATIVES HERPES PROTEASE INHIBITORS
ECSP003373A (en) HIV THERAPY

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure